Nimer Alkhatib1,2, Nancy K Sweitzer3,4, Christopher S Lee5, Brian Erstad1,6, Marion Slack1,6, Mahdi Gharaibeh1, Jason Karnes6, Walter Klimecki7, Kenneth Ramos4,8, Ivo Abraham9,10,11. 1. Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Drachman Hall B-306, 1295 N. Martin Ave, Tucson, AZ, 85721, USA. 2. College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan. 3. Sarver Heart Center, University of Arizona, Tucson, AZ, USA. 4. College of Medicine, University of Arizona, Tucson, AZ, USA. 5. Connell School of Nursing, Boston College, Chestnut Hill, MA, USA. 6. Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA. 7. Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA. 8. Institute of BioSciences and Technology, Texas A&M University, Houston, TX, USA. 9. Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Drachman Hall B-306, 1295 N. Martin Ave, Tucson, AZ, 85721, USA. abraham@pharmacy.arizona.edu. 10. College of Medicine, University of Arizona, Tucson, AZ, USA. abraham@pharmacy.arizona.edu. 11. Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA. abraham@pharmacy.arizona.edu.
Abstract
OBJECTIVE: The Beta-Blocker Evaluation Survival Trial showed no survival benefit for bucindolol in New York Heart Association (NYHA) class III/IV heart failure (HF) with reduced ejection fraction, but subanalyses suggested survival benefits for non-Black subjects and Arg389 homozygotes. We conducted an ex ante economic evaluation of Arg389 targeted treatment with bucindolol versus carvidolol, complementing a previous ex ante economic evaluation of bucindolol preceded by genetic testing for the Arg389 polymorphism, in which genetic testing prevailed economically over no testing. METHODS: A decision tree analysis with an 18-month time horizon was performed to estimate the cost effectiveness/cost utility of trajectories of 100%, 50%, and 0% of patients genetically tested for Arg389 and comparing bucindolol with empirical carvedilol treatment as per prior BEST subanalyses. Incremental cost-effectiveness/cost-utility ratios (ICERs/ICURs) were estimated. RESULTS: Race-based analyses for non-White subjects at 100% testing showed a loss of (0.04) life-years and (0.03) quality-adjusted life-years (QALYs) at an incremental cost of $2185, yielding a negative ICER of ($54,625)/life-year and ICUR of ($72,833)/QALY lost; at 50%, the analyses showed a loss of (0.27) life-years and (0.16) QALYs at an incremental cost of $1843, yielding a negative ICER of ($6826)/life-year and ICUR of ($11,519)/QALY lost; at 0%, the analyses showed a loss of (0.33) life-years and (0.30) QALYs at an incremental cost of $1459, yielding a negative ICER of ($4421)/life-year and ICUR of ($4863)/QALY lost. Arg389 homozygote analyses at 100% testing showed incremental gains of 0.02 life-years and 0.02 QALYs at an incremental cost of $378, yielding an ICER of 18,900/life-year and ICUR of $18,900/QALY gained; at 50%, the analyses showed a loss of (0.24) life-years and (0.09) QALYs at an incremental cost of $1039, yielding a negative ICER of ($4329)/life-year and ICUR of ($9336)/QALY lost; at 0%, the analyses showed a loss of (0.33) life-years and (0.30) QALYs at an incremental cost of $1459, yielding a negative ICER of ($4421)/life-year and ICUR of ($4863)/QALY lost. CONCLUSION: This independent ex ante economic evaluation suggests that genetically targeted treatment with bucindolol is unlikely to yield clinicoeconomic benefits over empirical treatment with carvedilol in NYHA III/IV HF.
OBJECTIVE: The Beta-Blocker Evaluation Survival Trial showed no survival benefit for bucindolol in New York Heart Association (NYHA) class III/IV heart failure (HF) with reduced ejection fraction, but subanalyses suggested survival benefits for non-Black subjects and Arg389 homozygotes. We conducted an ex ante economic evaluation of Arg389 targeted treatment with bucindolol versus carvidolol, complementing a previous ex ante economic evaluation of bucindolol preceded by genetic testing for the Arg389 polymorphism, in which genetic testing prevailed economically over no testing. METHODS: A decision tree analysis with an 18-month time horizon was performed to estimate the cost effectiveness/cost utility of trajectories of 100%, 50%, and 0% of patients genetically tested for Arg389 and comparing bucindolol with empirical carvedilol treatment as per prior BEST subanalyses. Incremental cost-effectiveness/cost-utility ratios (ICERs/ICURs) were estimated. RESULTS: Race-based analyses for non-White subjects at 100% testing showed a loss of (0.04) life-years and (0.03) quality-adjusted life-years (QALYs) at an incremental cost of $2185, yielding a negative ICER of ($54,625)/life-year and ICUR of ($72,833)/QALY lost; at 50%, the analyses showed a loss of (0.27) life-years and (0.16) QALYs at an incremental cost of $1843, yielding a negative ICER of ($6826)/life-year and ICUR of ($11,519)/QALY lost; at 0%, the analyses showed a loss of (0.33) life-years and (0.30) QALYs at an incremental cost of $1459, yielding a negative ICER of ($4421)/life-year and ICUR of ($4863)/QALY lost. Arg389 homozygote analyses at 100% testing showed incremental gains of 0.02 life-years and 0.02 QALYs at an incremental cost of $378, yielding an ICER of 18,900/life-year and ICUR of $18,900/QALY gained; at 50%, the analyses showed a loss of (0.24) life-years and (0.09) QALYs at an incremental cost of $1039, yielding a negative ICER of ($4329)/life-year and ICUR of ($9336)/QALY lost; at 0%, the analyses showed a loss of (0.33) life-years and (0.30) QALYs at an incremental cost of $1459, yielding a negative ICER of ($4421)/life-year and ICUR of ($4863)/QALY lost. CONCLUSION: This independent ex ante economic evaluation suggests that genetically targeted treatment with bucindolol is unlikely to yield clinicoeconomic benefits over empirical treatment with carvedilol in NYHA III/IV HF.
Authors: Jonathan P Piccini; William T Abraham; Christopher Dufton; Ian A Carroll; Jeff S Healey; Dirk J van Veldhuisen; William H Sauer; Inder S Anand; Michel White; Stephen B Wilton; Ryan Aleong; Michiel Rienstra; Steven K Krueger; Felix Ayala-Paredes; Yaariv Khaykin; Bela Merkely; Vladimir Miloradović; Jerzy K Wranicz; Leonard Ilkhanoff; Paul D Ziegler; Gordon Davis; Laura L Emery; Debra Marshall; David P Kao; Michael R Bristow; Stuart J Connolly Journal: JACC Heart Fail Date: 2019-04-29 Impact factor: 12.035
Authors: Stephen B Liggett; Jeanne Mialet-Perez; Surai Thaneemit-Chen; Stewart A Weber; Scott M Greene; Danielle Hodne; Bradley Nelson; Jennifer Morrison; Michael J Domanski; Lynne E Wagoner; William T Abraham; Jeffrey L Anderson; John F Carlquist; Heidi J Krause-Steinrauf; Laura C Lazzeroni; J David Port; Philip W Lavori; Michael R Bristow Journal: Proc Natl Acad Sci U S A Date: 2006-07-14 Impact factor: 11.205
Authors: Jeanne Mialet Perez; Deborah A Rathz; Natalia N Petrashevskaya; Harvey S Hahn; Lynne E Wagoner; Arnold Schwartz; Gerald W Dorn; Stephen B Liggett Journal: Nat Med Date: 2003-09-14 Impact factor: 53.440
Authors: Hazel L White; Rudolf A de Boer; Azhar Maqbool; Darren Greenwood; Dirk J van Veldhuisen; Richard Cuthbert; Stephen G Ball; Alistair S Hall; Anthony J Balmforth Journal: Eur J Heart Fail Date: 2003-08 Impact factor: 15.534
Authors: Milton Packer; Michael B Fowler; Ellen B Roecker; Andrew J S Coats; Hugo A Katus; Henry Krum; Paul Mohacsi; Jean L Rouleau; Michal Tendera; Christoph Staiger; Terry L Holcslaw; Ildiko Amann-Zalan; David L DeMets Journal: Circulation Date: 2002-10-22 Impact factor: 29.690
Authors: Alexander Göhler; Benjamin P Geisler; Jennifer M Manne; Mikhail Kosiborod; Zefeng Zhang; William S Weintraub; John A Spertus; G Scott Gazelle; Uwe Siebert; David J Cohen Journal: Value Health Date: 2008-07-18 Impact factor: 5.725
Authors: Michael J Domanski; Heidi Krause-Steinrauf; Barry M Massie; Prakash Deedwania; Dean Follmann; David Kovar; David Murray; Ron Oren; Yves Rosenberg; James Young; Michael Zile; Eric Eichhorn Journal: J Card Fail Date: 2003-10 Impact factor: 5.712